AstraZeneca reverses $285 mln charge as cancer trial starts
LONDON, Sept 4
LONDON, Sept 4 (Reuters) - AstraZeneca has reversed a previous pre-tax impairment charge of $285 million after launching a final-stage Phase III clinical trial for the experimental drug olaparib in ovarian cancer.
The drug had earlier looked unlikely to get to market but confidence in its prospects has revived following more recent tests. AstraZeneca said on Wednesday that the reversal of the charge would be excluded from core earnings.
- U.S.' Kerry voices 'regret' to India over diplomat case |
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Medical bills underlie 60 percent of U.S. bankrupts: study
- Mega Millions winners in Georgia, California to split $648 million |